FDA approval has been granted for an adjuvant pembrolizumab–belzutifan combination in high-risk, post-surgery clear cell kidney cancer, according to a Dana-Farber-backed report. The regimen pairs an immune checkpoint inhibitor with a hypoxia-inducible factor-2α (HIF-2α) blocker to target residual disease after nephrectomy. The approval expands the adjuvant toolset for clear cell renal cell carcinoma and underscores continued regulator focus on combination strategies in the perioperative setting, where endpoints often hinge on preventing recurrence rather than shrinking existing tumors.